{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=21", "query": { "intervention": "ABI-007(Abraxane)", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 2448, "total_pages": 245, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T15:16:19.584Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03064854", "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "PDR001", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Canakinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-05-24", "completion_date": "2021-07-28", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-10-15T15:16:19.584Z", "location_count": 5, "location_summary": "Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03064854" }, { "nct_id": "NCT01204996", "title": "A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection", "type": "DRUG" }, { "name": "CNTO888 + gemcitabine", "type": "DRUG" }, { "name": "CNTO888 + Paclitaxel and carboplatin", "type": "DRUG" }, { "name": "CNTO888 + docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2010-05", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2012-05-30", "last_synced_at": "2026-10-15T15:16:19.584Z", "location_count": 2, "location_summary": "Detroit, Michigan • Tacoma, Washington", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204996" }, { "nct_id": "NCT02065466", "title": "Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Brain Metastases" ], "interventions": [ { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-07", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2016-04-21", "last_synced_at": "2026-10-15T15:16:19.584Z", "location_count": 2, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065466" }, { "nct_id": "NCT00369551", "title": "Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Lung", "Bronchoalveolar Cell Lung Cancer", "Large Cell Lung Cancer", "Stage II Non-small Cell Lung Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer" ], "interventions": [ { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2006-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-03-06", "last_synced_at": "2026-10-15T15:16:19.584Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00369551" }, { "nct_id": "NCT05239182", "title": "9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "9-ING-41", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anwaar Saeed", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2022-01-26", "completion_date": "2024-02-04", "has_results": true, "last_update_posted_date": "2025-07-17", "last_synced_at": "2026-10-15T15:16:19.584Z", "location_count": 2, "location_summary": "Fairway, Kansas • Pittsburgh, Pennsylvania", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05239182" }, { "nct_id": "NCT00005970", "title": "Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Adenocarcinoma", "HER2 Positive Breast Carcinoma", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7" ], "interventions": [ { "name": "Aromatase Inhibition Therapy", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Tamoxifen Citrate", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3436, "start_date": "2000-05-19", "completion_date": "2010-01-27", "has_results": false, "last_update_posted_date": "2020-08-14", "last_synced_at": "2026-10-15T15:16:19.584Z", "location_count": 154, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005970" }, { "nct_id": "NCT04926467", "title": "Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Anakinra", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2021-07-23", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-15T15:16:19.584Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04926467" }, { "nct_id": "NCT04067544", "title": "Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chemotherapy-induced Peripheral Neuropathy", "Breast Cancer Female", "Gynecologic Cancer" ], "interventions": [ { "name": "Acupuncture", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2019-11-05", "completion_date": "2020-08-12", "has_results": true, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-10-15T15:16:19.584Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04067544" }, { "nct_id": "NCT04083599", "title": "GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Solid Tumor", "Non-Small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Melanoma", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "GEN1042", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2019-09-17", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-15T15:16:19.584Z", "location_count": 23, "location_summary": "Anchorage, Alaska • Los Alamitos, California • San Diego, California + 19 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Los Alamitos", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT04083599" }, { "nct_id": "NCT02383212", "title": "Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Advanced Malignancies" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Hypofractionated radiotherapy", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2015-02-02", "completion_date": "2019-11-18", "has_results": false, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-10-15T15:16:19.584Z", "location_count": 40, "location_summary": "Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 31 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02383212" } ] }